U.S. Department of Health & Human Services
05/16/2022 | Press release | Distributed by Public on 05/17/2022 16:00
Selected Adverse Events Reported after COVID-19 Vaccination
Multiple studies and reviews of data from vaccine safety monitoring systems continue to show that vaccines are safe. As a result, the agency will refocus enhanced surveillance and safety monitoring efforts toward children and adolescents.
As of May 12, 2022, there have been 968 reports in VAERS among people younger than age 18 years under review for potential cases of myocarditis and pericarditis. Of those, 250 remain under review. Through confirmation of symptoms and diagnostics by provider interview or review of medical records, 668 reports have been verified. See the following for a breakdown of reports by age group.
5-11 years: 22 verified reports of myocarditis after 18,439,324 doses administered
12-15 years: 348 verified reports of myocarditis after 23,288,179 doses administered
16-17 years: 298 verified reports of myocarditis after 12,687,076 doses administered
As the COVID-19 vaccines are authorized for younger children, CDC and FDA will continue to monitor for and evaluate reports of myocarditis and pericarditis after COVID-19 vaccination and will share more information as it becomes available. Learn more about myocarditis and pericarditis, including clinical considerations, after mRNA COVID-19 vaccination.